122 related articles for article (PubMed ID: 35854663)
1. Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms.
Park R; Amin M; Trikalinos NA
J Neuroendocrinol; 2022 Jul; 34(7):e13178. PubMed ID: 35854663
[TBL] [Abstract][Full Text] [Related]
2. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Kesavan M; Grover P; Lam WS; Claringbold PG; Turner JH
Endocr Relat Cancer; 2021 Jun; 28(7):521-527. PubMed ID: 34010146
[TBL] [Abstract][Full Text] [Related]
3. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
5. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
6. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
8. Secondary hematological malignancies associated with temozolomide in patients with glioma.
Momota H; Narita Y; Miyakita Y; Shibui S
Neuro Oncol; 2013 Oct; 15(10):1445-50. PubMed ID: 23519741
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
11. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
[TBL] [Abstract][Full Text] [Related]
13. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Spada F; Maisonneuve P; Fumagalli C; Marconcini R; Gelsomino F; Antonuzzo L; Campana D; Puliafito I; Rossi G; Faviana P; Messerini L; Barberis M; Fazio N
Endocrine; 2021 Apr; 72(1):268-278. PubMed ID: 32700133
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B
Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182
[TBL] [Abstract][Full Text] [Related]
17. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
[TBL] [Abstract][Full Text] [Related]
18. Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms".
Chatzellis E; Daskalakis K; Angelousi A; Tsoli M; Alexandraki KI; Wachula E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2020; 110(1-2):158-160. PubMed ID: 31597137
[No Abstract] [Full Text] [Related]
19. Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
La Salvia A; Brizzi MP; Muratori L; Trevisi E; Di Maio M; Scagliotti GV
Endokrynol Pol; 2019; 70(4):380-383. PubMed ID: 30359462
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]